Our Group

Dr. Stamatatos’s lab focuses on the clinical evaluation of novel HIV vaccine candidates designed to elicit protective antibody responses. Our clinical studies are conducted in both uninfected individuals and people living with HIV, building on extensive preclinical research in transgenic mice engineered to express human B cell receptors. To gain a comprehensive understanding of the immune responses elicited by our vaccines, we employ a wide range of experimental approaches, including AlphaFold3-based structural modeling, next-generation deep sequencing, and advanced immunological, molecular, and cellular techniques.